Enlicitide: complete guide

Enlicitide is a macrocyclic peptide PCSK9 inhibitor approved by FDA as Lipfendra in July 2026. This guide covers its structure, mechanism, labeled use, trials and label safety data.

Complete guide5 min read

Key takeaway

FDA approved enlicitide as Lipfendra on July 15, 2026. In the CORALreef Lipids trial of 2,904 adults, it lowered LDL cholesterol by 56% more than placebo at week 24. In the CORALreef HeFH trial of 303 adults with inherited high cholesterol, the placebo-adjusted drop was 59%.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Lipfendra on July 15, 2026.” (this article)
ClassHeart & blood
Body systemsHeart & vessels
Studies cited2 in this article · 2 across 1 article on Enlicitide
Related productsResearch peptide catalog

Enlicitide is a macrocyclic peptide that blocks PCSK9, a protein that clears LDL receptors from liver cells. FDA approved it in July 2026 as Lipfendra to lower LDL cholesterol in adults with hypercholesterolemia. This guide covers its structure, mechanism, approval, trials and label safety data, with sources checked on November 17, 2026.

Quick answer: Enlicitide is a prescription PCSK9 inhibitor built as a ring-shaped peptide rather than an antibody. Its label covers lowering LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, alongside diet and exercise. It has no boxed warning and no listed contraindications. Whether it reduces heart attacks or deaths is not yet known.

Vitrapep does not sell enlicitide; this page is a reference summary of published research and regulatory information.

What is enlicitide?

The Lipfendra label states: “Enlicitide is a macrocyclic peptide that binds to PCSK9” (Lipfendra label, 2026). A macrocyclic peptide is a chain of amino acid building blocks closed into a large ring.

The drug substance is enlicitide decanoate, a salt. The label gives its formula as C92H129FN14O17 and its molecular weight as 1,722.12 g/mol. PubChem lists the enlicitide ion itself as C82H110FN14O15+, with a molecular weight of 1,550.8 g/mol (PubChem CID 164933665). Its research code in Merck’s trials was MK-0616. Our guide to types of peptides explains how cyclic peptides differ from linear ones.

Drugs@FDA lists the original approval of Lipfendra on July 15, 2026. The application is NDA 220848, held by MSD (Drugs@FDA). FDA lists it among its novel drug approvals for 2026 (FDA, 2026). Merck announced the approval the next day (Merck, 2026).

Table 1

Enlicitide: key facts

Fact Detail
Structure type Macrocyclic peptide (ring-shaped), supplied as the decanoate salt
Class PCSK9 inhibitor
Molecular formula C92H129FN14O17 (enlicitide decanoate, label); C82H110FN14O15+ (enlicitide ion, PubChem)
Molecular weight 1,722.12 g/mol (decanoate, label); 1,550.8 g/mol (ion, PubChem)
First FDA approval July 15, 2026 (Lipfendra, NDA 220848)
Brand names (US) Lipfendra

How does enlicitide work?

LDL receptors sit on liver cells and pull LDL cholesterol out of the blood. The label explains that PCSK9 binds these receptors “to promote LDLR degradation within the liver.” Fewer receptors means more LDL cholesterol left in circulation.

Enlicitide blocks that step. By stopping PCSK9 from binding LDL receptors, the label says, it “increases the number of LDLRs available to clear LDL-C” (Lipfendra label, 2026). The same target is hit by the monoclonal antibody PCSK9 inhibitors that the label mentions. Enlicitide differs in being a much smaller peptide molecule. Our explainer on how peptides work covers peptide-protein binding.

What is enlicitide approved for?

Lipfendra “is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia.” The indication adds: “including heterozygous familial hypercholesterolemia (HeFH).” HeFH is an inherited form of high LDL cholesterol.

The approval rests on LDL cholesterol lowering, not on heart outcomes. Merck’s release states: “It is not yet known if LIPFENDRA can reduce the risk of cardiovascular morbidity and mortality.” The label adds that safety and effectiveness have not been established in children.

What did the key trials show?

CORALreef Lipids. This human phase 3 trial was multicenter, double-blind, randomized and placebo-controlled. The label describes 2,904 adults with hypercholesterolemia and either a past major cardiovascular event or raised risk of a first one. They were randomized 2:1 to enlicitide or placebo. At baseline, 97% were already taking a statin (NCT05952856).

The primary end point was the mean percent change in LDL cholesterol from baseline to week 24. The adjusted between-group difference was −55.8 percentage points (95% CI, −60.9 to −50.7; P < 0.001). Non-HDL cholesterol, apolipoprotein B and lipoprotein(a) also fell significantly more with enlicitide. The authors reported that adverse event rates “did not appear to differ between the groups” (Navar et al., 2026).

CORALreef HeFH. This phase 3 trial randomized 303 adults with heterozygous familial hypercholesterolemia, and 293 completed it. At week 24, the placebo-adjusted change in LDL cholesterol was −59.4% (95% CI, −65.6% to −53.2%; P < .001). Adverse events, serious adverse events and dropouts for adverse events were similar between groups (Ballantyne et al., 2026; NCT05952869).

What side effects does the label list?

The Lipfendra label has no boxed warning, no warnings and precautions section, and lists no contraindications. In CORALreef Lipids, the label says adverse reaction rates “were similar between those treated with LIPFENDRA and those receiving placebo.”

In CORALreef HeFH, two reactions were more common with Lipfendra than with placebo:

  • dizziness (9% vs 4%); and
  • diarrhea (7% vs 2%).

In both trials, similar shares of patients on Lipfendra and on placebo stopped treatment because of an adverse reaction (Lipfendra label, 2026).

What is enlicitide’s regulatory status, and how is it used in research?

Lipfendra is a prescription drug in the United States. Drugs@FDA lists its marketing status as prescription. FDA includes it in its list of novel drug approvals for 2026.

Research continues in the CORALreef program, which Merck says covers more than 19,000 participants. The largest study is CORALreef Outcomes, a phase 3 cardiovascular outcomes trial. ClinicalTrials.gov lists it as active, not recruiting, with 14,550 participants and primary completion in November 2029 (NCT06008756). Merck also lists extension, pediatric and combination trials.

Frequently asked questions about enlicitide

Is enlicitide a peptide?

Yes. The label calls it a macrocyclic peptide, a ring-shaped chain of amino acid building blocks.

Is enlicitide FDA approved?

Yes. Drugs@FDA lists the original approval of Lipfendra on July 15, 2026.

How is enlicitide different from antibody PCSK9 inhibitors?

Both block PCSK9. Enlicitide is a small macrocyclic peptide, while the earlier drugs in the class are large monoclonal antibodies.

Does enlicitide lower heart attack risk?

That is not yet known. Merck states that an ongoing trial, CORALreef Outcomes, is studying cardiovascular events.

Does enlicitide have a boxed warning?

No. The label lists no boxed warning and no contraindications. Dizziness and diarrhea were more common than with placebo in the HeFH trial.

What to know now

  • Structure: macrocyclic peptide; decanoate salt 1,722.12 g/mol.
  • Approval: Lipfendra, July 15, 2026; prescription only.
  • Mechanism: binds PCSK9 so more LDL receptors stay on liver cells.
  • Label: lowering LDL cholesterol in adults with hypercholesterolemia, including HeFH.
  • Evidence: placebo-adjusted LDL cholesterol falls of about 56% and 59% at week 24.
  • Safety: no boxed warning; dizziness and diarrhea more common in the HeFH trial.

What we’re watching

CORALreef Outcomes (NCT06008756), listed as active, not recruiting, with primary completion in November 2029. Any Lipfendra label update that adds outcome data. Related guides: rusfertide, another peptide approved in 2026, and angiotensin II.

More for heart & vessels

All 13 compounds for heart & vessels

Sources: Merck Sharp & Dohme LLC 2026, LIPFENDRA (enlicitide) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 220848 (LIPFENDRA) . Retrieved November 17, Drugs@FDA: NDA 220848 (LIPFENDRA); U.S. Food and Drug Administration 2026, Novel drug approvals for 2026; Merck & Co 2026; National Center for Biotechnology Information 2026, PubChem compound summary for CID 164933665, enlicitide; Navar 2026, The New England Journal of Medicine, 394; Merck Sharp & Dohme LLC 2023; Ballantyne 2026, JAMA, 335; Merck Sharp & Dohme LLC 2023; Merck Sharp & Dohme LLC 2023. All 10 citations

Back to the research library

References

  1. Merck Sharp & Dohme LLC. (2026). LIPFENDRA (enlicitide) prescribing information (revised 7/2026). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220848Orig1s000lbl.pdf
  2. U.S. Food and Drug Administration. Drugs@FDA: NDA 220848 (LIPFENDRA). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220848
  3. U.S. Food and Drug Administration. (2026). Novel drug approvals for 2026. Retrieved November 17, 2026, from https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
  4. Merck & Co., Inc. (2026, July 16). Merck’s LIPFENDRA (enlicitide) is the first and only once-daily oral PCSK9 inhibitor approved by the U.S. FDA to reduce LDL-C in adults with hypercholesterolemia [News release]. https://s2.q4cdn.com/584635680/files/doc_news/Mercks-LIPFENDRA-enlicitide-is-the-First-and-Only-Once-Daily-Oral-PCSK9-Inhibitor-Approved-by-the-U-S--FDA-to-Reduce-LDL-C-in-Adults--Z6KOQ.pdf
  5. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 164933665, enlicitide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/164933665
  6. Navar, A. M., et al. (2026). A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. The New England Journal of Medicine, 394(6), 529-539. https://doi.org/10.1056/NEJMoa2511002
  7. Merck Sharp & Dohme LLC. (2023). A study of enlicitide decanoate (MK-0616 oral PCSK9 inhibitor) in adults with hypercholesterolemia (MK-0616-013) CORALreef Lipids (ClinicalTrials.gov ID NCT05952856). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT05952856
  8. Ballantyne, C. M., et al. (2026). Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: A randomized clinical trial. JAMA, 335(2), 129-139. https://doi.org/10.1001/jama.2025.20620
  9. Merck Sharp & Dohme LLC. (2023). A study of enlicitide decanoate (MK-0616 oral PCSK9 inhibitor) in adults with heterozygous familial hypercholesterolemia (MK-0616-017/CORALreef HeFH) (ClinicalTrials.gov ID NCT05952869). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT05952869
  10. Merck Sharp & Dohme LLC. (2023). Enlicitide decanoate (MK-0616 oral PCSK9 inhibitor) cardiovascular outcomes study (MK-0616-015) CORALreef Outcomes (ClinicalTrials.gov ID NCT06008756). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT06008756